THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS
The aim of the study was to assess the efficacy and safety of ART regimens that included different doses of the drug 6НР with the reception of QD, in comparison with the scheme of ART, containing, PhAZT, to select the daily dose 6НР in conducting phase III clinical trials.Patients and methods. 125 p...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2019-03-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/848 |
| _version_ | 1797702631038124032 |
|---|---|
| author | A. V. Kravchenko N. V. Sizova S. V. Minaeva O. A. Kozyrev F. I. Nagimova O. S. Efremova D. A. Gusev E. V. Ovsyannikova |
| author_facet | A. V. Kravchenko N. V. Sizova S. V. Minaeva O. A. Kozyrev F. I. Nagimova O. S. Efremova D. A. Gusev E. V. Ovsyannikova |
| author_sort | A. V. Kravchenko |
| collection | DOAJ |
| description | The aim of the study was to assess the efficacy and safety of ART regimens that included different doses of the drug 6НР with the reception of QD, in comparison with the scheme of ART, containing, PhAZT, to select the daily dose 6НР in conducting phase III clinical trials.Patients and methods. 125 patients were randomized to 25 people in 4 groups, depending on the daily dose of the drug 6НР (600, 800, 1000, 1200 mg), and in the comparison group (phosphazide). For a daily dose of the drug 6НР the study was blind. All patients, in addition to the studied drugs were receiving 3TC and EFV. The effectiveness of ART regimens was assessed by the proportion of patients with HIV RNA <50 copies/ml and CD4+lymphocyte increase after 24 weeks of therapy. Results. The use of ART scheme, which included 6НР + 3TС + EFV, was highly effective regardless of the daily dose of the drug 6НР, and is comparable to the effectiveness of the comparison mode (PhAZT+3TC+EFV). More than 95.5% of patients receiving 600 mg and 800 mg of the drug 6НР QD, after 24 weeks of therapy, the level of HIV RNA was < 50 copies/ml (in the comparison group – 87.5%). In patients of all groups there was a significant increase in the median CD4+lymphocytes. The maximum result of increasing the median CD4 + lymphocyte count (164 cells/µl) was observed in patients receiving the drug 6НР – 600 mg/day. All the studied modes was safe because of the 24-week study made up 94% of the patients receiving 6НР, and 96% of receiving PhAZT. Only 1 patient (1%) receiving the maximum daily dose 6НР (1200 mg), marked AES possibly related to study medication, and which led to the cancellation of the treatment.Conclusions. The effectiveness and safety of all modes of ART did not depend on the daily dose of the drug 6НР and was comparable to the comparison scheme, which included PhAZT. The maximum virological and immunological response after 24 weeks of therapy was achieved in patients receiving the drug 6НР at a dose of 600 mg QD in the ART scheme. The drug 6HP is recommended for phase III study in a daily dose of 600 mg in the ART. |
| first_indexed | 2024-03-12T04:52:52Z |
| format | Article |
| id | doaj.art-67538076bf734a378f62ddf13116a4ed |
| institution | Directory Open Access Journal |
| issn | 2072-6732 |
| language | Russian |
| last_indexed | 2024-03-12T04:52:52Z |
| publishDate | 2019-03-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj.art-67538076bf734a378f62ddf13116a4ed2023-09-03T09:18:31ZrusJournal InfectologyЖурнал инфектологии2072-67322019-03-01111334010.22625/2072-6732-2019-11-1-33-40701THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTSA. V. Kravchenko0N. V. Sizova1S. V. Minaeva2O. A. Kozyrev3F. I. Nagimova4O. S. Efremova5D. A. Gusev6E. V. Ovsyannikova7Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора.Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями.Нижегородский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями.Волгоградский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями.Республиканский центр по профилактике и борьбе со СПИД и инфекционными заболеваниями.Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора.Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями.АО «Производственно-коммерческая Ассоциация АЗТ».The aim of the study was to assess the efficacy and safety of ART regimens that included different doses of the drug 6НР with the reception of QD, in comparison with the scheme of ART, containing, PhAZT, to select the daily dose 6НР in conducting phase III clinical trials.Patients and methods. 125 patients were randomized to 25 people in 4 groups, depending on the daily dose of the drug 6НР (600, 800, 1000, 1200 mg), and in the comparison group (phosphazide). For a daily dose of the drug 6НР the study was blind. All patients, in addition to the studied drugs were receiving 3TC and EFV. The effectiveness of ART regimens was assessed by the proportion of patients with HIV RNA <50 copies/ml and CD4+lymphocyte increase after 24 weeks of therapy. Results. The use of ART scheme, which included 6НР + 3TС + EFV, was highly effective regardless of the daily dose of the drug 6НР, and is comparable to the effectiveness of the comparison mode (PhAZT+3TC+EFV). More than 95.5% of patients receiving 600 mg and 800 mg of the drug 6НР QD, after 24 weeks of therapy, the level of HIV RNA was < 50 copies/ml (in the comparison group – 87.5%). In patients of all groups there was a significant increase in the median CD4+lymphocytes. The maximum result of increasing the median CD4 + lymphocyte count (164 cells/µl) was observed in patients receiving the drug 6НР – 600 mg/day. All the studied modes was safe because of the 24-week study made up 94% of the patients receiving 6НР, and 96% of receiving PhAZT. Only 1 patient (1%) receiving the maximum daily dose 6НР (1200 mg), marked AES possibly related to study medication, and which led to the cancellation of the treatment.Conclusions. The effectiveness and safety of all modes of ART did not depend on the daily dose of the drug 6НР and was comparable to the comparison scheme, which included PhAZT. The maximum virological and immunological response after 24 weeks of therapy was achieved in patients receiving the drug 6НР at a dose of 600 mg QD in the ART scheme. The drug 6HP is recommended for phase III study in a daily dose of 600 mg in the ART.https://journal.niidi.ru/jofin/article/view/848вич-инфекцияартпрепарат 6нр |
| spellingShingle | A. V. Kravchenko N. V. Sizova S. V. Minaeva O. A. Kozyrev F. I. Nagimova O. S. Efremova D. A. Gusev E. V. Ovsyannikova THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS Журнал инфектологии вич-инфекция арт препарат 6нр |
| title | THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS |
| title_full | THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS |
| title_fullStr | THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS |
| title_full_unstemmed | THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS |
| title_short | THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS |
| title_sort | results of the efficacy and safety of the new russian drug 6нр in the antiretroviral therapy regimens of hiv infected patients |
| topic | вич-инфекция арт препарат 6нр |
| url | https://journal.niidi.ru/jofin/article/view/848 |
| work_keys_str_mv | AT avkravchenko theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT nvsizova theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT svminaeva theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT oakozyrev theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT finagimova theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT osefremova theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT dagusev theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT evovsyannikova theresultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT avkravchenko resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT nvsizova resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT svminaeva resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT oakozyrev resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT finagimova resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT osefremova resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT dagusev resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients AT evovsyannikova resultsoftheefficacyandsafetyofthenewrussiandrug6nrintheantiretroviraltherapyregimensofhivinfectedpatients |